Allergy Thera. Share News (AGY)
AGY Share
AGY Share
AGY Share
AGY Share
AGY
AGY Share
AGY Level 2
AGY Live
AGY Broker
AGY Directors
AGY Financial
AGY
AGY Short
AGY
Last checked at -
Pharmaceutical firm Allergy Therapeutics reported broadly flat revenues and profits for the six months ended 31 December, as a result of weakness in its core German market. First half revenue was £27.4m, slightly higher than £27.3m in 2009. Weakness in the euro also had a £1.1m impact on turnover.
Read moreHay fever treatment specialist Allergy Therapeutics posted an operating profit for the year to June of £1.5m (2009: loss £5.1m) and cut losses to £116,000 from £11.4m. "On the regulatory front, the submission in March 2009 of Pollinex Quattro Grass, our ultra-short course four injection grass alle
Read moreLONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN), a specialist pharmaceutical company focused on allergy vaccination, said Thursday, it expects to report revenue of GBP40.7 million, and an operating profit, for the year ended June 30, adding that the results was in-line with current market expe
Read moreDow Jones smallcap news is now on Twitter, allowing you to catch up on the news away from your desk. Go to http://twitter.com/DJ_UK_Smallcaps WILLS & CO STOCKBROKERS LTD, a small cap share dealer, has been declared to be in default by the Financial Services Compensation Scheme, four months afte
Read more(Adds analyst comment, detail.) By Jason Douglas Of DOW JONES NEWSWIRES LONDON (Dow Jones)--Drug developer Allergy Therapeutics PLC (AGY.LN) Thursday said it agreed to buy its Swiss distributor, in one of its first steps in a new strategy to bolster its position in Europe. Allergy sa
Read moreLONDON (Dow Jones)--Allergy Therapeutics PLC (AGY.LN) said Thursday it has agreed to acquire Teomed AG of Switzerland for a consideration of GBP700,000. MAIN FACTS: -The consideration for the acquisition of Teomed will comprise an initial cash payment of GBP500,000 on signing and a deferred
Read moreTIDMAGY RNS Number : 6201O Allergy Therapeutics PLC 01 July 2010 ? Thursday 1 July 2010 Allergy Therapeutics plc ("Allergy Therapeutics" or "the Company") Allergy Therapeutics to acquire Teomed AG Expands Eur
Read moreCairn Energy chief executive Sir Bill Gammell has raised nearly £3m from a share sale. Sir Bill sold 721,042 shares in the oil and gas producer and explorer at 414.4p each. He retains 3.21m shares, which is equivalent to 0.23% of the company's share capital. There have been two other sales by Si
Read moreBeowulf, owner of several exploration projects in Sweden, continues to believe in the commercial prospects for its asset portfolio which has increased in both quantity and quality as well as resource type. Losses grew to £520,000 in 2009 from £399,000 the year before, but it says future price tren
Read moreAlliance Trust's investment stance means that it is always in danger of trailing more heavily geared rivals when the stock market runs sharply ahead. However, on a rolling total return basis it continues to fare well ? ranked first out of its six largest peers over both one and two years. Further,
Read moreAllergy vaccination group Allergy Therapeutics narrowed half year losses and said it is well placed to capitalise on the investments of the past. Pre-tax losses narrowed to £11.44m in the six month ended 30 June compared with a loss of £20.24m last time. Revenues increased by 22% to £37.8m, on a
Read moreBig profits and a maiden dividend have sent entertainment products distributor MBL charging higher Thursday. The supplier of CDs, DVDS and games reported a 42% hike in pre-tax profit for the year ended 31 March 2009 to £8.1m on revenue up 77.5% to £143.6m. Its major competitor, Entertainment UK, t
Read moreA number of directors at Booker have sold millions worth of shares the same day as the cash and carry group said profits and net debt remain in line with expectations. Finance director Jonathan Prentis and operating director Bryn Satherley each made £2.63m, selling 7.5m shares at 35.00p. Commercia
Read moreA Latin American business group is to take control of hay fever treatment developer Allergy Therapeutics through the injection of £12.5m of new funds at 12p per share. Azure Ventures, an investment vehicle of the Weinstein family of Chile, whose interests include a group of pharmaceutical companies
Read more
Last checked at